MASHINIi

MEI Pharma, Inc..

MEIP.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

MEI Pharma, Inc. is a pharmaceutical company focused on the development of novel cancer therapies. The company's pipeline includes clinical-stage drug candidates targeting various hematologic malignancies and solid tumors. Their research and development efforts are primarily directed towards discove...Show More

Ethical Profile

Mixed.

MEI Pharma, Inc. is a clinical-stage pharmaceutical company dedicated to developing novel cancer therapies, aligning with a focus on 'Better Health for All.' The company invested $52.5 million in research and development in FY2023. They are advancing drug candidates like voruciclib, which was generally well-tolerated in a Phase 1 study, and ME-344. Initial clinical data for ME-344 in metastatic colorectal cancer showed 25% of evaluable patients had no disease progression at Week 16, addressing unmet needs in cancer treatment. Information on other ethical areas like fair labor, environmental impact, or supply chain practices is not publicly available.

Value Scores

Better Health for All-20
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing20
-100100
Honest & Fair Business-40
-100100
Kind to Animals-50
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-20
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech10
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

-20

MEI Pharma's core business is entirely devoted to health improvement, focusing on developing novel drug candidates for cancer therapies, specifically voruciclib and ME-344, which target resistance mechanisms in acute myeloid leukemia and metastatic colorectal cancer.

1
The company's entire product pipeline is dedicated to addressing these serious health conditions. Research and development expenses, which represent the company's investment in health innovation, were $52.5 million in fiscal year 2023, a decrease from $85.6 million in fiscal year 2022, attributed to the wind-down of zandelisib activities.
2
In terms of safety, a clinical study evaluating ME-344 in combination therapy reported that the treatment was generally well-tolerated.
3
However, two out of 23 patients (approximately 8.7%) discontinued therapy due to adverse events (fatigue and sepsis).
4
Common adverse events included fatigue (35% overall, 13% Grade 3/4) and abdominal pain (13% overall, 9% Grade 3/4).
5

Fair Money & Economic Opportunity

0

No evidence available to assess MEI Pharma, Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No evidence available to assess MEI Pharma, Inc. on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

20

Corrective action plans for complaints, non-conformances, recalls, or deviations are completed within three business days.

1
No specific quantitative data is provided for fair trade certifications, audit frequency, forced or child labor incidents, traceability coverage, ethical clause coverage, high-risk materials spend, or supplier diversity spend.
2

Honest & Fair Business

-40

MEI Pharma has a whistleblower policy

1
and an anti-corruption policy
2
, but specific details regarding their strength, enforcement, or effectiveness, such as hotline usage or training frequency, are not provided. The board of directors includes five independent members out of six, representing approximately 83% of the board.
3
The company's financial statements for the fiscal year ended June 30, 2024, were audited by Deloitte & Touche LLP
4
, providing third-party verification of financial claims
5
, but the percentage of revenue, assets, or subsidiaries covered is not explicitly stated.

Kind to Animals

-50

MEI Pharma conducts animal testing, specifically pre-clinical trials on animals, including mice, for drug candidates like ME-344.

1
The company's policy is to comply with FDA regulations and ICH guidance regarding animal welfare.
2
Annually, the company uses between 10,000 and 15,000 animals in testing.

No War, No Weapons

0

No evidence available to assess MEI Pharma, Inc. on No War, No Weapons.

Planet-Friendly Business

-20

The company's ESG summaries and sustainability reports do not mention any specific regulatory actions, violations, fines, or compliance issues.

1

Respect for Cultures & Communities

0

No evidence available to assess MEI Pharma, Inc. on Respect for Cultures & Communities.

Safe & Smart Tech

10

Lite Strategy Inc. (formerly MEI Pharma) holds EU-U.S., UK Extension to the EU-U.S., and Swiss-U.S. Data Privacy Framework (DPF) certifications.

1
There are no documented incidents of unauthorized data use.
2
The company provides users with strong control over their personal data, including the ability to opt-out of communications, request changes or deletion of data, and exercise rights under European and state privacy laws, with requests addressed within 30 days.
3
Lite Strategy retains personal data only for the length of time required to fulfill the purpose for which it was collected, with cookie data retained for 1 year and unsuccessful job applicant data for the duration of the hiring process unless consent is given.
4
The company demonstrates good compliance with applicable regulations, including GDPR and CCPA, and uses Standard Contractual Clauses for international data transfers.
5

Zero Waste & Sustainable Products

0

No evidence available to assess MEI Pharma, Inc. on Zero Waste & Sustainable Products.

Own MEI Pharma, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.